Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection

A case report

Jong Youb Lim, MDb,c,∗, Young-Ho Lim, MDb, Eun-Hi Choi, MD, PhDb

Abstract

Introduction: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired autoimmune disorder with progressive weakness. Acute-onset CIDP resembles Guillain-Barre syndrome (GBS), a rapidly progressive disorder, and follows a chronic course. To our knowledge, no case of acute-onset CIDP in hantavirus and hepatitis B virus (HBV) coinfection has been reported previously.

Clinical findings: We report a case of acute-onset CIDP that was initially diagnosed as GBS.

Diagnoses: A 44-year-old male logger complained of acute quadriplegia and dyspnea. Mechanical ventilation was initiated. He was an HBV carrier with mild elevation of hepatic enzyme, and positive for hantavirus antibody. He was diagnosed with GBS and immunoglobulin therapy was administered.

Interventions: After 8 months, quadriplegia and hyposthesia recurred. Immunoglobulin therapy at this time had no effect, but steroid therapy had some effect.

Outcomes: A diagnosis of CIDP was made. After 2 months, severe extremity pain and dyspnea developed again, and steroid pulse therapy was initiated.

Conclusion: Besides GBS, acute-onset CIDP can occur with hantavirus and HBV coinfection. Patients with this coinfection in whom GBS has been initially diagnosed should be followed up for a long time, because of the possibility of relapse or deterioration, and acute-onset CIDP should always be considered.

Abbreviations: CIDP = chronic inflammatory demyelinating polyneuropathy, EP = electrophoresis, GBS = Guillain-Barre syndrome, HBV = hepatitis B virus, HFRS = hemorrhagic fever with renal syndrome, Ig = immunoglobulin, MAG = myelin-associated glycoprotein, MGUS = monoclonal gammopathy of undetermined significance, MRC = medical research council, NCS = nerve conduction studies, TRF = treatment-related fluctuation.

Keywords: case report, chronic inflammatory demyelinating polyneuropathy, hantavirus, hepatitis B virus

1. Introduction

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired autoimmune disorder with relapsing or progressive neuropathy with proximal and distal weakness.[1] Guillain-Barre syndrome (GBS) is a rapidly progressive disorder showing bilateral and symmetrical weakness of the limbs, usually after gastrointestinal or upper respiratory infection.[2] CIDP with an acute presentation resembling GBS followed by chronic or relapsing features is referred to as acute-onset CIDP.[3]

Hantavirus causes hemorrhagic fever with renal syndrome (HFRS) in Asia and Europe or hantavirus cardiopulmonary syndrome in America.[4] Neurological complications of HFRS are headache, vertigo, epileptic seizures, and cerebral hemorrhage.[5] GBS can occur after HFRS.[6–8] Hepatitis B virus (HBV), although less frequent than hepatitis C virus, is known to cause GBS and CIDP, and the deposition of immune complexes is one possible pathomechanism.[9] GBS was mainly associated with acute HBV infection[10,11] and CIDP, with chronic HBV infection.[12] GBS was also found in chronic HBV infection.[13]

However, there are no studies reporting the relationship between CIDP and hantavirus and the development of acute-onset CIDP after HBV infection. In this paper, we present a case of acute-onset CIDP in a patient with hantavirus and HBV coinfection.

2. Case report

A 44-year-old male logger was admitted to the neurology department because of rapidly progressive quadriplegia and dyspnea. Muscle weakness progressed from distal to proximal muscles, and he needed to use the accessory muscles for breathing. He could not stand without assistance. Manual muscle test
revealed medical research council (MRC) grade 2 power in all extremities except ankles, which had grade 1 power. Hypesthesia was also noted. Intubation and mechanical ventilation were started. Brain computed tomography showed no abnormal findings. He was an HBV carrier, and laboratory test showed mild elevation of hepatic enzymes (<100 IU/L). Elevated protein level with no white blood cell was found in the cerebrospinal fluid. Nerve conduction studies (NCS) showed abnormal findings such as no response or delayed latency in all 4 extremities (Table 1).

Fever, malaise, anorexia, and subconjunctival hemorrhage were other complaints. Leukocytosis, decreased plateletcrit, increased C-reactive protein and blood urea nitrogen, hypalbuminemia, elevated prothrombin time, hematuria, and proteinuria were shown in laboratory tests. The enlargement of both kidneys and splenomegaly were noted in ultrasound imaging. Hantavirus-specific immunoglobulin (Ig) M antibody was detected using the indirect immunofluorescence antibody technique. He was diagnosed with GBS, and intravenous Ig therapy was initiated. Serum protein electrophoresis (EP) showed diffusely increased gamma-globulin fraction, suggesting polyclonal gammopathy. Ig analysis showed IgM in the normal range but increased IgG and IgA levels. After about 1 month of rehabilitation, he had nearly full recovery, evident by MRC grade 4 and independent walking. He was discharged and followed up in the outpatient department thereafter. He took adequate rest and did not continue working as a logger.

After 8 months of initial admission, quadriplegia and hypesthesia recurred. He was admitted to the neurology department. NCS findings indicated worsening. Sural nerve biopsy showed no infiltration of inflammatory cells and no evidence of atrophy or degeneration. With the provisional diagnosis of fluctuating GBS, Ig therapy was started but it had no effect. Steroid and immunosuppressant were administered, following which there was some improvement. Serum EP suggested polyclonal gammopathy. No monoclonal gammopathy was found in immunofixation EP. Anti-myelin-associated glycoprotein (MAG) IgM antibody and cryoglobulin were not detected. He was finally diagnosed with CIDP. After rehabilitation, he was discharged with MRC grade 3 power.

He had no symptoms for 2 months even without medication. However, severe extremity pain and dyspnea developed again, and he was admitted to the intensive care unit. He complained of weakness but the MRC grade was still grade 3. NCS showed further aggravation (Table 2). Steroid pulse therapy was started. Serum and immunofixation EP showed the similar pattern as that during the previous admission. Thereafter, he was transferred to the rehabilitation department with medication (Prednisolone 20 mg and Azathioprine 100 mg per day), and repetitive transcranial magnetic stimulation for 10 days decreased his pain to a tolerable level. He was discharged with MRC grade 4. Written informed consent was obtained from the patient prior to the publication of this case report.

### Table 1

| Sensory      | Right                | Latency, msec | Amplitude, µV | Velocity, m/s | Left                | Latency, msec | Amplitude, µV | Velocity, m/s |
|--------------|----------------------|---------------|---------------|---------------|---------------------|---------------|---------------|---------------|
| Median       |                      | N/R<sup>†</sup> | N/R<sup>†</sup> |               |                     | N/R<sup>†</sup> | N/R<sup>†</sup> |               |
| Median       |                      | 3.70<sup>‡</sup> | 3.2<sup>‡</sup> | 28.4<sup>‡</sup> |                     |               |               |               |
| Median       |                      | 22.85<sup>‡</sup> | 0.2<sup>‡</sup> | N/T<sup>‡</sup> |                     |               |               |               |
| Median       |                      | 17.55<sup>‡</sup> | 0.5<sup>‡</sup> | N/T<sup>‡</sup> |                     |               |               |               |
| Median       |                      | 10.60<sup>‡</sup> | 1.1<sup>‡</sup> | 38.7<sup>‡</sup> |                     |               |               |               |
| Median       |                      | 9.25<sup>‡</sup> | 0.7<sup>‡</sup> | 43.0<sup>‡</sup> |                     |               |               |               |
| Ulnar        |                      | N/R<sup>†</sup> | N/R<sup>†</sup> |               |                     | N/R<sup>†</sup> | N/R<sup>†</sup> |               |
| Ulnar        |                      | 4.30<sup>‡</sup> | 5.0<sup>‡</sup> | 44.1<sup>‡</sup> |                     |               |               |               |
| Ulnar        |                      | 3.70<sup>‡</sup> | 3.2<sup>‡</sup> | 28.4<sup>‡</sup> |                     |               |               |               |
| Ulnar        |                      | 33.00<sup>‡</sup> | 0.3<sup>‡</sup> | 65.3<sup>‡</sup> |                     |               |               |               |
| Ulnar        |                      | 21.30<sup>‡</sup> | 1.8<sup>‡</sup> | 18.4<sup>‡</sup> |                     |               |               |               |
| Ulnar        |                      | 16.20<sup>‡</sup> | 1.4<sup>‡</sup> | 37.8<sup>‡</sup> |                     |               |               |               |
| Peroneal     |                      | N/R<sup>†</sup> | N/R<sup>†</sup> |               |                     | N/R<sup>†</sup> | N/R<sup>†</sup> |               |
| Peroneal     |                      | 23.10<sup>‡</sup> | 1.2<sup>‡</sup> | 18.4<sup>‡</sup> |                     |               |               |               |
| Peroneal     |                      | 33.00<sup>‡</sup> | 0.4<sup>‡</sup> | N/T<sup>‡</sup> |                     |               |               |               |
| Peroneal     |                      | 22.85<sup>‡</sup> | 0.3<sup>‡</sup> | 42.9<sup>‡</sup> |                     |               |               |               |
| Sural        |                      | 24.30<sup>‡</sup> | 0.8<sup>‡</sup> | 30.8<sup>‡</sup> |                     |               |               |               |
| Sural        |                      | 28.45<sup>‡</sup> | 0.3<sup>‡</sup> | 42.9<sup>‡</sup> |                     |               |               |               |

<sup>†</sup>Proximal stimulation showed no response.

### Table 2

| Sensory      | Right                | Latency, msec | Amplitude, µV | Velocity, m/s | Left                | Latency, msec | Amplitude, µV | Velocity, m/s |
|--------------|----------------------|---------------|---------------|---------------|---------------------|---------------|---------------|---------------|
| Median       |                      | N/R<sup>†</sup> | N/R<sup>†</sup> |               |                     | N/R<sup>†</sup> | N/R<sup>†</sup> |               |
| Median       |                      | 39.40<sup>‡</sup> | 0.3<sup>‡</sup> | 65.3<sup>‡</sup> |                     |               |               |               |
| Median       |                      | 37.60<sup>‡</sup> | 0.9<sup>‡</sup> | 15.8<sup>‡</sup> |                     |               |               |               |
| Median       |                      | 21.30<sup>‡</sup> | 1.8<sup>‡</sup> | 18.4<sup>‡</sup> |                     |               |               |               |
| Median       |                      | 23.10<sup>‡</sup> | 1.2<sup>‡</sup> | 18.4<sup>‡</sup> |                     |               |               |               |
| Median       |                      | 24.30<sup>‡</sup> | 0.8<sup>‡</sup> | 30.8<sup>‡</sup> |                     |               |               |               |

<sup>†</sup>Proximal stimulation showed no response.
3. Discussion

In the acute phase, CIDP and GBS have many common symptoms and signs, and the time from onset to maximum severity helps differentiate the 2 conditions. In GBS, disease severity reaches maximum within 4 weeks, but in CIDP, the initial disease progression lasts for more than 8 weeks. However, 16% of CIDP patients, described as acute-onset CIDP, show rapidly progressive weakness within 4 weeks from onset, and 18% of CIDP patients present with relapsing weakness. Meanwhile 8% to 16% of GBS patients show one or more deteriorations after initial improvement, described as treatment-related fluctuations (TRFs). In such cases, it is difficult to distinguish between these 2 conditions.

Some differentiating factors have been suggested in previous reports. The 1st TRF in GBS occurred within 8 weeks from onset, and not more than 2 episodes of TRF were experienced. Ig and plasma exchange treatment were effective in both CIDP and GBS, but steroid therapy was effective only in CIDP. Some CIDP patients, who showed improvement by initial treatment with Ig, relapsed into a chronic stage and improved only after steroid treatment was begun. In NCS, CIDP showed marked improvement by initial treatment, described as treatment-related fluctuations (TRFs). In such cases, it is difficult to distinguish between these 2 conditions.

Our patient showed rapid and relapsing weakness. First deterioration after symptom improvement was after 8 months from 1st admission. Although he showed initial improvement with Ig therapy, he responded only to steroid therapy during the 1st deterioration. These findings suggested acute-onset CIDP rather than GBS. The initial diagnosis of GBS was wrong, and the correct diagnosis was CIDP.

Monoclonal gammopathy of undetermined significance (MGUS) is found in 10% to 20% of CIDP cases. In MGUS, one of the Ig classes, such as IgM, IgG, or IgA, is selectively elevated. More than half of the IgM-MGUS patients have anti-MAG IgM antibodies. The relationship between CIDP and MGUS is relatively established in IgM type but not in the IgG or IgA type. If the time to peak of neuropathy is less than 6 months and if the course is relapsing, then the diagnosis of MGUS is less likely, and steroid therapy alone is seldom effective.

Our patient showed not monoclonal but polyclonal gammopathy with elevation of both IgG and IgA. Anti-MAG IgM antibody was not detected. Steroid therapy was effective in the 1st deterioration. Polyclonal gammopathies are usually associated with reactive or inflammatory processes, and viral infection in this patient might have caused polyclonal gammopathy.

Sural nerve biopsy showed nonspecific findings. A nerve biopsy may be useful in atypical CIDP cases, but it has limited diagnostic value in CIDP with relatively low positive rates. A negative finding for cryoglobulin could rule out HBV-related cryoglobulinemic vasculitis, which is known to manifest peripheral neuropathy.

He was an HBV carrier with normal levels of hepatic enzymes. During the 1st admission, hepatic enzyme levels increased mildly and were below 100IU/L. Before the 1st admission, the patient did not complain of any weakness or sensory change in any extremity. His weakness was not gradual as is generally seen in HBV-related CIDP patients. Clinical and laboratory findings suggested acute HFRS, and the presence of hantavirus-specific IgM antibody confirmed acute hantavirus infection. The simultaneous symptoms of CIDP brought him to the hospital in time, and intensive care prevented the further progression of HFRS. Other possible causes of CIDP were ruled out, and we propose that HBV infection can induce CIDP and that hantavirus can cause acute-onset CIDP.

4. Conclusion

Besides GBS, acute-onset CIDP can occur after hantavirus and HBV coinfection. Although the patient was in the HBV carrier state and hantavirus infection was acute, the result of coinfection was rapid and severe enough to need mechanical ventilation. Patients with this coinfection who are 1st diagnosed with GBS should be followed up for a long time, because of the possibility of relapse or deterioration, and acute-onset CIDP should always be considered.

References

[1] Dimachkie MM, Barohn RJ. Chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol 2013;15:350–66.
[2] Eldar AH, Chapman J. Guillain Barre syndrome and other immune mediated neuropathies: diagnosis and classification. Autoimmun Rev 2014;13:525–30.
[3] Anañani M, Katriji B. Acute-onset chronic inflammatory demyelinating polyneuropathy: an electrophysiological study. Muscle Nerve 2015;32:900–5.
[4] Manigold T, Vial P. Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology. Swiss Med Wkly 2014;144:w13937.
[5] Surujunou M, Watson DC, Chera P, et al. Hantavirus infections for the clinician: from case presentation to diagnosis and treatment. Curr Vet Microbiol 2012;38:317–29.
[6] Förslund T, Saltevo J, Anttinen J, et al. Complications of nephropathia epemdsica: three cases. J Intern Med 1992;232:87–90.
[7] Esselink RA, Gerding MN, Brouwers PJ, et al. Guillain-Barre syndrome associated with hantavirus infection. Lancet 1994;343:180–1.
[8] Rabaud C, May T, Hoen B, et al. Guillain-Barre syndrome associated with hantavirus infection. Clin Infect Dis 1995;20:477–8.
[9] Stühlen JP. Neuromuscular disorders associated with hepatitis B virus infection. J Clin Neuromusc Dis 2011;15:26–37.
[10] Yimam KK, Merriman RB, Todd Frederick R. A rare case of acute hepatitis B virus infection causing guillain-barre syndrome. Gastroenterol Hepatol (N Y) 2013;9:121–3.
[11] Ray G, Ghosh B, Bhattacharyya R. Acute hepatitis B presenting as Guillain-Barre syndrome. Indian J Gastroenterol 2003;22:2228.
[12] Taşcilar NF, Acimai E, Koruse O. Kronik infiamlatari demiyelinizan polinörapti ileプレゼント olan hepatitis b virus enfeksiyonsu. Duzce Med J 2010;12:73–7.
[13] Chroń E, Themopoulos C, Papapetropoulos S, et al. A case of relapsing Guillain-Barre syndrome associated with exacerbation of chronic hepatitis B virus hepatitis. J Neurol Sci 2003;9:408–10.
[14] Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010;74:1680–6.
[15] Odaaka M, Yuki N, Hirata K. Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barre syndrome. J Neurol 2003;250:913–6.
[16] Ruts L, van Koningsvel R, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barre syndrome with treatment related fluctuations. Neurology 2003;65:138–40.
[17] van Doorn PA. Treatment of Guillain-Barre syndrome and CIDP. J Peripher Nerv Syst 2005;10:113–27.
[18] Alexander JK, Alshubalil AF, Santhamoorothy P, et al. Corticosteroids can help distinguish between Guillain-Barre syndrome and first attack of chronic inflammatory demyelinating neuropathy: an illustrative case report. Med Princ Pract 2008;17:422–4.
[19] Mori K, Hattori N, Sugiuara M, et al. Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 2002;58:979–82.
[20] Zurkovic SA, Pelner AG, Jacob T, et al. Chronic inflammatory demyelinating polyneuropathy and ventilatory failure: report of seven new cases and review of the literature. Acta Neurol Scand 2011;124:39–63.
[21] Hadden R, Nobile-Orazio E, Sommer C, Gilhus NE, Barnes MP, Brainin M, et al. Paraproteinaemic demyelinating neuropathies. European Handbook of Neurological Management. Vol. 1 2nd ed. West Sussex, UK: Wiley-Blackwell; 2011:351–361.

[22] Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 2015;86:973–85.

[23] O’Connell TX, Horita TJ, Kastrivi B. Understanding and interpreting serum protein electrophoresis. Am Fam Physician 2005;71:103–12.

[24] Mazzaro C, Dal Maso L, Urraro T, et al. Hepatitis B virus related cryoglobulinemic vasculitis: a multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC. Dig Liver Dis 2016;48:780–4.